Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2

Status

Recruiting 2Active not recruiting 2

Sponsor Class

NIH 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 4

Conditions

Squamous Cell Carcinoma of Head and Neck 12Oropharyngeal Neoplasms 11Lung Neoplasms 8Laryngeal Neoplasms 8Carcinoma 8Mouth Neoplasms 7Carcinoma, Non-Small-Cell Lung 7Hypopharyngeal Neoplasms 6Nasopharyngeal Carcinoma 5Mesothelioma, Malignant 5Urinary Bladder Neoplasms 4Pancreatic Neoplasms 4Uterine Cervical Neoplasms 3Lymphoid Interstitial Pneumonia 3Gallbladder Neoplasms 3Triple Negative Breast Neoplasms 2Salivary Gland Neoplasms 2Paranasal Sinus Neoplasms 2Ovarian Neoplasms 2Medulloblastoma 2Ganglioneuroblastoma 2Cholangiocarcinoma 2Adenocarcinoma of Lung 2Vulvar Neoplasms 1Vaginal Neoplasms 1Tongue Neoplasms 1Testicular Neoplasms 1Teratoma 1Stomatitis 1Stage III Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v6 and v7 1

Interventions

Gemcitabine 33Cisplatin 22pembrolizumab 21Magnetic Resonance Spectroscopy 18Specimen Handling 16durvalumab 12Mitomycin 10enfortumab vedotin 9avelumab 9Nivolumab 9Cystoscopy 9Fluorouracil 8Carboplatin 8Radiation 7Cystectomy 7Radiotherapy 6Immunoglobulin G 6Docetaxel 6Disulfides 6atezolizumab 5Transurethral Resection of Bladder 5Mitozytrex 5Biopsy 5tremelimumab 4sacituzumab govitecan 4erdafitinib 4dehydroftorafur 4Standard of Care 4Platinum 41,2-diaminocyclohexaneplatinum II citrate 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Urinary Bladder Neoplasms × 1,2-diaminocyclohexaneplatinum II citrate × 90 days × Clear all
NCT06770582 2026-06-03

Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial

National Cancer Institute (NCI)

Phase 2 Recruiting
160 enrolled
Genitourinary

Urinary Bladder Neoplasms

NCT03775265 2026-05-29

Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer

National Cancer Institute (NCI)

Phase 3 Active not recruiting
475 enrolled
Genitourinary

Urinary Bladder Neoplasms

NCT04216290 2026-05-22

A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes, INSPIRE Trial

National Cancer Institute (NCI)

Phase 2 Active not recruiting
11 enrolled
Genitourinary

Urinary Bladder Neoplasms

NCT07097142 2026-05-04

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study

NRG Oncology

Phase 3 Recruiting
486 enrolled
Genitourinary

Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡